Study S001085

Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07668414
Acronym: AMAZE 7
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 650
Start: 2026-09-22
Primary completion: 2028-10-10
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity
Interventions: DRUG:Zenagamtide; DRUG:Semaglutide; DRUG:Placebo (matched to semaglutide); DRUG:Placebo (matched to zenagamtide)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1313-7968

Registered primary outcomes

Relative change in body weight [From week 0 to week 84]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.